

Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables

- A alleles 12, 22
 - evolution 24
- A antigen 4
 - acute myeloid leukaemia 49
 - carbohydrate determinants 14–17
 - enzymatic degradation 50–1
 - expression on acquired B cells 48
 - incompatible in malignancy 66
 - in plasma 33
 - structure **14, 15**
 - subgroups 33, **34**, 35–8
- A genes
 - frequency 30, **31**
 - interaction with B genes 40–1
- A¹ consensus sequence 22
- A₁ 28–30
- A₂ 28–31
 - determinants 30
 - phenotype 29
 - red cell biochemistry 30
- A² allele 22, 29
- A₃ 33, **34**, 35
- A4GALT gene 166, 168, 169
 - mutations 172, 519
- cisAB 42–3
- A/B heterozygotes, allelic enhancement 41
- A_{bantu} 29, **34**, 36
- A(B) phenotype 41–2
- ABCB6 487, **488**, 490–1
- ABCB6 gene 490
- ABCG2 487, 488–9
 - functions 489, 491
- ABCG2 gene 488–9
 - mutations 488, **489**
- ABH antibodies 51–7
- ABH antigen
 - acquired changes 47–50
 - acute myeloid leukaemia 49–50
 - enzymatic degradation 50–1
 - expression
 - on ectodermal/endodermal/mesodermal tissues 64, 65
 - on leucocytes 63–4
 - on platelets 64
 - on tumours 64–6
 - fetal 32
 - genetic control in body 64, 65
 - glycoconjugates 13–14
 - glycosyltransferases 17–18
 - secretion 31–3
 - secretors 32–3
 - structure 13–17
 - Type 1 16
 - Type 2 16, **17**
 - Type 3 16–17
 - Type 4 17
 - Type 6 17
- ABH non-secretors 19, **20**, 25, 32
 - bacterial infections 66
 - Le^a antigen 26
 - viral infection resistance 66–7
- ABH-active oligosaccharides, Ii antigens 470
- ABO antibodies
 - autoantibodies 53
 - clinical significance 52–3
 - monoclonal 54
- ABO antigens
 - acquired changes 47–50
 - biosynthesis 11–13, 21
 - disease associations 66–8
 - inheritance 11
 - loss in tumours 65
 - molecular genetics 21–4
 - secretion 31–3
 - secretor status 32
 - structure 11–13
 - transplantation 53–4
- ABO, historical aspects 11–13
- ABO gene
 - alleles 12, 22
 - cDNA 22
 - frequency 32
 - products in membrane of Golgi apparatus 23
 - protein products 22
- chromosome 9 13, 24
- CpG island 23
- evolution 24
- fusion genes 24
- genomic organisation 21, 22
- linkage 24
- non-human primates 24
- ABO incompatibility 52–3, 64
- ABO monoclonal antibodies 54
- ABO phenotype
 - clotting anomalies 67–8
 - disease associations 66–8
 - frequency 30–1
 - malaria 67
 - pancreatic cancer 68
 - prediction 25
- ABO pseudogene 24
- abortion, habitual spontaneous with P antibodies 174
- ABTI 500, 502
 - frequency **501**
- acetylcholinesterase (AChE) 354, 356
 - red cell deficiency 356
- N-acetylgalactosamine *see* GalNAc

- ACHE* gene 354
 chromosome location 355
 mutation 356
 acquired B 47–9, 517–18
 causes 48–9
 polyagglutination 49
 serological characteristics 47–8
 acute myeloid leukaemia (AML)
 49–50
 monosomy 7 387
 Tn polyagglutination 519
 adhesion molecules 8
 adult i phenotype 472–3
 GCNT2 gene mutations 473
 AE1 red cell anion exchanger 336
A_{el} 33, 34, 35, 37
A_{end} 33, 34, 35–6
A_{finn} 34, 36
A_h 44, 46
A_{int} 30
ALe^b structure 14
 allelic enhancement 41
A_m 33, 34, 35, 36–7
 amino acids, codes 1, 3
A_{mos} 40
 Amt genes 236
An^a 411, 417, 418
 anaemia
 CD151 deficiency 463
 see also autoimmune haemolytic
 anaemia (AIHA); congenital
 dyserthropoietic anaemia
 (CDA); haemolytic anaemia
 anti-A 28, 32, 51–2
 lectins 55–6
 monoclonal 54
 anti-A₁ 28, 53
 monoclonal 54
 anti-A,B 52
 anti-ABTI 502
 anti-ALe^b 61
 anti-An^a 418
 anti-AnWj 453–4
 monoclonal 454
 anti-At^a 502
 anti-Au^a 264
 anti-B 51–2
 lectins 56
 monoclonal 54
 anti-Bg 513
 anti-Bi 498
 anti-By 498
 anti-c 231
 anti-C 209, 211, 231
 anti-C4 402
 anti-CD 212
 anti-CD20 53
 anti-CD44 450, 451
 monoclonal 450, 451, 452
 anti-CD99 362
 anti-CD108, monoclonal 467
 anti-CD151 461–2
 anti-CDE 212
 anti-ce 211
 anti-cE 212
 anti-Ce 211
 anti-CE 211–12
 anti-Ch 400, 401, 406
 anti-Cl^a 133
 anti-Co3 387
 anti-Co4 386–7
 anti-Co^a 387
 anti-Co^b 387
 anti-CR1 441
 anti-Cr^a 433
 anti-CRAG 432
 anti-CRAM 432
 anti-CROV 432
 anti-CROZ 432
 anti-CRUE 432
 anti-Cs^a 444, 446
 anti-Cs^b 446
 anti-C^w 213
 anti-D 140–1, 182, 184, 228–9
 clinical significance 230–1
 D epitope structure 204–5
 D+ patients 232
 genetics 229–30
 haemolytic disease of the fetus and
 newborn 230–1
 human monoclonal 229
 IgG 229, 230, 231
 IgM 476
 heavy chain variable region 230
 immunoprophylaxis 230
 monoclonal 196, 199, 229
 stimulation by DVa 206
 anti-D immunoglobulin 207, 231
 anti-Dantu 130
 anti-Dh^a 418
 anti-Di^a 339–40
 monoclonal 340
 anti-Di^b 339–40
 monoclonal 340
 anti-Do^a 380–1
 anti-Do^b 380–1
 monoclonal 381
 anti-DOLG 380
 anti-DOMR 380
 anti-DOYA 380
 anti-DSLK 140
 anti-Duclos 140
 anti-D^w 228
 anti-e 185, 211, 231
 anti-E 184, 209–10, 211, 219, 231
 transfusion 211
 anti-ELO 344
 anti-Emm 502
 anti-En^a 106–7, 109–10
 clinical significance 110
 anti-En^aFR 110
 anti-En^aFS 109, 110, 111
 anti-En^aTS 109, 110
 anti-ENAV 132
 anti-ENEP 132
 anti-ENEV 132
 anti-Er3 493, 494
 anti-Er^a 493, 494
 anti-Er^b 494
 anti-ERIK 131
 anti-f 211
 anti-Far 133
 anti-FPTT 218
 anti-Fy3 312–13
 anti-Fy4 313
 anti-Fy5 312, 313
 anti-Fy6, monoclonal 312, 313
 anti-Fy^a 310, 312
 monoclonal 311
 anti-Fy^b 309, 310–11
 monoclonal 311
 anti-G 212, 231
 anti-Ge2 413, 420
 monoclonal 420
 anti-Ge3 413
 anti-Ge4 414
 monoclonal 420
 anti-GIL 485
 anti-Go^a 227–8
 anti-GUTI 432
 anti-Gy^a 379, 380, 381
 anti-H 54–5
 monoclonal 55
 anti-HAG 132
 anti-He 117
 anti-Hi 55, 476
 anti-HI 55, 476
 anti-Hil 120, 127, 128
 anti-HJK 498
 anti-HLA-B7 512
 anti-Hop 118
 anti-Hr 210
 anti-hr^B 210, 211
 anti-Hr^B 210
 anti-Hr_o 218, 222

- anti-hr^s 211
 anti-Hut 126, 127
 anti-Hy 379, 380, 381
 anti-i 469, 470, 475, 476
 cold lymphocytotoxin 474
 haemagglutination inhibition 474
 monoclonal 475
 structure 475–6
 anti-I 469, 470, 474–6
 cold lymphocytotoxin 474
 lectin 475
 structure 475–6
 anti-I (Ma) 474
 anti-IFC 429–30
 anti-IN3 450, 451
 anti-IN4 450, 451, 452
 anti-In^a 452
 anti-In^b 450, 451, 452
 anti-IP 173
 anti-IP1 173, 476
 anti-I^T 476
 anti-I^TP 173, 476
 anti-I^TP1 173
 anti-j 476
 anti-JAL 218
 anti-JFV 498
 anti-Jk3 329–30
 anti-Jk^a 327–8
 monoclonal 328
 anti-Jk^b 327–8
 monoclonal 328
 anti-JMH 465, 466, 467
 anti-Jo^a 379, 380, 381
 anti-JONES 498
 anti-Jr^a 487–8
 anti-Js^a 287
 anti-Js^b 287
 anti-k 285
 anti-K 282, 283, 284–5
 clinical significance 284–5
 human monoclonal 284
 non-red cell immune 284
 anti-KEL11 287–288
 anti-KEL17 288
 anti-KEL18 288
 anti-KEL19 288–9
 anti-KEL22 289
 anti-KEL23 289
 anti-KEL24 288
 anti-KEL25 289
 anti-KEL26 289
 anti-KEL27 289
 anti-KEL28 289
 anti-KEL29 289
 anti-KEL30 289
 anti-KEL31 289–90
 anti-KEL32 290
 anti-KEL33 290
 anti-KEL34 290
 anti-KEL35 290
 anti-KEL36 290
 anti-KEL38 289
 anti-Kg 498
 anti-Km 296
 anti-Kn^a 444
 anti-Kp^a 285–6
 anti-Kp^b 285, 286, 292
 anti-Kp^c 286
 anti-Ku 271, 282, 291
 anti-Kx 296
 anti-Lan 489, 490, 500
 anti-Le^a 12
 human 60
 monoclonal 60–1
 renal failure in bone marrow
 transplantation 62
 renal transplant rejection 61–2
 anti-Le^b 12, 61
 monoclonal 61
 renal transplant rejection 61–2
 anti-Lepore 119
 anti-LKE 171
 anti-Ls^a 417
 anti-Lu3 266, 267
 anti-Lu5 265
 anti-Lu6 264, 265
 anti-Lu7 265
 anti-Lu8 264
 anti-Lu9 264
 anti-Lu12 265
 anti-Lu13 265
 anti-Lu14 264
 anti-Lu16 265–6
 anti-Lu17 266
 anti-Lu20 266
 anti-Lu21 266
 anti-Lu^a 263
 anti-Lu^b 263
 anti-LW 193, 391, 395–6
 animal 396
 anti-LW^a 392, 394, 395
 anti-LW^{ab} 392, 393–4, 395
 monoclonal 396
 anti-LW^b 395
 anti-M 103–4, 116–17, 136–7
 alloantibodies 137
 autoantibodies 137
 clinical significance 137
 glucose-dependent 138
 lectins 138–9
 monoclonal 138
 recombinant 138
 anti-MAM 500, 503
 anti-MAR 213
 anti-MARS 132
 anti-McC^a 444
 anti-McC^b 442
 anti-Me 478
 anti-M^c 117
 anti-MER2 462, 463
 anti-M^g 114
 anti-Mi^a 129
 anti-MINY 128
 anti-Mit 134
 anti-MNTD 134
 anti-Mt^a 133
 anti-MTP 503
 anti-Mur 125, 128
 anti-MUT 127
 anti-M^v 133
 anti-N 103–4, 137
 alloantibodies 137
 autoantibodies 137
 clinical significance 137–8
 glucose-dependent 138
 lectins 138–9
 monoclonal 138
 recombinant 138
 renal dialysis 137–8
 anti-Nf 137–8
 anti-Nob 118
 anti-Ny^a 133
 anti-OK2 458
 anti-OK3 458
 anti-Ok^a 457, 458
 anti-Om 478
 anti-Or 134
 anti-Os^a 134
 anti-p 173
 anti-P 169–70
 early abortion association 174
 anti-P1 165, 166–7, 476
 monoclonal 167
 anti-pdl 225
 anti-PEL 503
 anti-P^k 167–8
 monoclonal 168
 anti-PPIP^k 172–3
 habitual spontaneous abortion 174
 anti-Pr 111, 477
 anti-Pt^a 497
 anti-PX2 171
 anti-RASM 498
 anti-Re^a 498
 anti-Rg 400, 401, 406

- anti-Rg1 404
 anti-Rg2 404
 anti-Rh 184, 228–32, 391, 476
 anti-Rh29 225
 anti-Rh35 218
 anti-Rh41 211
 anti-Ri^a 133
 anti-s 139
 anti-S 139
 anti-Sa 111, 477
 anti-SARA 498
 anti-SC1 373
 anti-SC2 373
 anti-SC4 373–4
 anti-s^D 134
 anti-Sd^a 505–6, 507
 anti-SERF 432
 anti-SI2 443
 anti-Sia-1b 477–8
 anti-St^a 131
 anti-T 136, 516–17
 anti-Tc^a 433
 anti-Tc^b 431
 anti-Tk, monoclonal 519
 anti-Tn 136
 anti-TSEN 128
 anti-U 111–12, 139–40
 anti-UI^a 287
 anti-U^s 140
 anti-U^r 140
 anti-V 214
 anti-Vel 500, 501–2
 anti-Vr 132
 anti-VS 214
 anti-Vw 127
 anti-WES^b 432
 anti-Wr^a 342
 anti-Wr^b 110, 340, 342–3
 anti-Xg^a 359, 361–2
 anti-Yt^a 354, 355, 356
 anti-Yt^{ab} 356
 anti-Yt^b 354, 355, 356
 anti-ZENA 432
 AnWj 269, 270, 449, 453–4, 502–3
 antibodies 453–4
 CD44 location 454
 development 453
 inheritance 453
 In(Lu) phenotype 453
 AnWj– phenotype 453
 A_{pac} 170
Aplysia depilans 475
 AQP1 gene 384
 AQP3 gene 485
 aquaglyceroporins 486
 aquaporin(s) 486
 aquaporin-1 (AQP1) 384, 387, 486
 expression 388
 functions 387–8
 structure 384, 385
 aquaporin-3 (AQP3) 384, 485
 ART4 376–7, 380
 ART4 gene 376
Ascaris suum 165
 asthma, Duffy antigens 317
 At^a 502
 frequency 501
 ataxia telangiectasia 140
 ATP-binding cassette transporters 487
 A-transferase *see* GTA
 Au^a 260, 263, 264–5
 Au^b 260, 263, 264–5
 Auberger antigens 260, 263, 264–5
 August *see* At^a
 autoanti-A 53
 autoanti-B 53
 autoanti-Co3, mimicking 387
 autoanti-D 232
 autoanti-Di^b 340
 autoanti-En^a 110
 autoanti-I 474–5
 autoanti-Jk3 330
 autoanti-Jk^a 328
 autoanti-Js^b 287
 autoanti-K, mimicking 285
 autoanti-Kp^b 286
 autoanti-Lan 490
 autoanti-LW 395
 autoanti-P 169–70
 autoanti-P^k 168
 autoanti-Pr 477
 autoanti-S 139
 autoanti-SC1 373
 autoanti-U 140
 autoanti-Vel 502
 autoanti-Wr^b 342–3
 autoimmune haemolytic anaemia (AIHA)
 ABO autoantibodies 53
 anti-I 474
 anti-I^T 476
 anti-I^TP 476
 anti-LW 395–6
 anti-N 137
 anti-Pr 111
 anti-Wr^a 342
 autoanti-Di^b 340
 autoanti-i 475
 autoanti-Jk3 330
 autoanti-Jk^a 328
 autoanti-Pr 477
 autoanti-S 139
 autoanti-SC1 373
 autoanti-U 140
 autoanti-Vel 502
 autoanti-Wr^b 342–3
 autoimmune idiopathic thrombocytopenic purpura (AITP) 271
 Kell phenotype 292
 A_w 33, 34, 37–8
 A_x 33, 34, 35, 36
 A_y 33, 34, 35, 37
 B antigen 4
 acute myeloid leukaemia 49
 carbohydrate determinants 14–17
 enzymatic degradation 50–1
 in plasma 33
 structure 14
 subgroups 38–40
 B genes
 alleles 12, 22, 38–40
 frequency 30, 31
 interaction with A genes 40–1
 B₃ 38–9
B3GALNT1 gene 171
B3GALT5 gene 171
B4GALNT2 gene 506, 508
 B(A) phenotype 41–2
 bacterial infections
 ABO 66
 CR1 445–6
 glycophorins 142
 Knops system 445–6
 P antigen receptors 173
 bacterial sialidase 516
Bacterioides fragilis 517
 BAEBL (VSTK) 421
 band 3
 chymotrypsin cleavage sites 344
 cluster formation 346
 concanavalin A binding protein 269
 Diego antigens 336, 339
 expression in gastric cancer 346
 function 345
 glycophorin A 142
 association 341–2
 glycophorin C 421
 glycophorin D 421
 ICAM-4 345, 392–3

- junctional macrocomplex 345
- LW system 396–7
- membrane complexes 193–4, 345–6
- South-East Asian ovalocytosis 347
- tetramers 345
- tissue distribution 346
- Wr^b expression 341–2
- band 3 deficiency 344–5
- Bandeiraea simplicifolia* 56, 139
- BARC 201–2, 227
- basal cell carcinoma, B-CAM 272
- basigin 457, 458
 - function 459
 - hyaluronan binding to CD44 459
 - malaria role 459
 - tissue distribution 459
- Bauhinia* 139
- B-CAM, Lu-gps 272
- BCAM gene 259
- Be^a 219, 227
- B_{el} 39–40
- benign ethnic neutropenia 315
- Bennett–Goodspeed *see* Bg
- Bg 512
- Bg^a 512
- Bg^b 512
- Bg^c 512
- B_h 44, 46
- Bi 496–497
- bladder cancer, *SLC14A1* susceptibility gene 331
- BLc^b, structure 14
- blood donors, testing 7
- blood group(s)
 - collections 4
 - definition 1
 - DNA analysis 5–7
 - molecular methods 5–7
 - clinical applications 5–7
 - current/future technologies 7
 - polymorphisms 8–9
 - systems 1, 2, 4
 - terminology 3–5
 - typing 5–7
- blood group alleles
 - polymorphisms 8–9
 - terminology 3
- blood group antigens
 - carbohydrate determinants 1
 - functions 7–9
 - identification number 3–4
 - protein determinants 1
 - structure 7–9
 - synthesis 1
 - terminology 3
- blood group collections 4
- blood group systems 2, 4
- blood transfusion
 - D variants 205–6
 - Duffy antigen storage lesions 317
 - e variants 211
 - see also* haemolytic transfusion reaction (HTR)
- Bloom syndrome 140
- B_m 23, 39
- B_{mos} 40
- Bombay phenotype 20, 21, 44–5
 - anti-H 54
 - distribution 45
 - frequency 45
 - genetics 45
 - glycosyltransferases 45
 - I antigen expression 471
 - serological characteristics 44–5
- BOW 399, 343, 343–4
- Bp^a 399, 343, 343–4
- breast cancer 317–18
 - basigin, hyaluronan and CD44 interactions 459
 - CD99 expression 367
 - Duffy antigens 317–18
 - immunotherapy 519
 - metastasis 474
 - T-/Tn-activated red cells 519
- bromelin, MNS antigen effects 106
- BSG gene 457, 458
- B-transferase *see* GTB
- Bu^a *see* SC2
- Burkitt's lymphoma 168, 173
- B_v 40
- B_w 40
- B_x 39
- Bx^a 496–497
- By 496–497
- C and c 182, 184–5, 207–9
 - frequency 207
 - phenotype prediction from DNA 208–209
 - polymorphism 208
 - sites on red cells 207, 208
- C1GALT1C1* gene 518
- C4 400, 401–4
 - deficiency 406–7
 - genes 404, 405–6
 - haplotype 403
 - molecular genetics 403
 - phenotypes 402
- polymorphisms 401
- RCCX genetic unit 404
- red cell coating 402
- C4a 401
- C4A gene 401, 403
 - deletion 406–7
 - systemic lupus erythematosus risk 406, 407
 - variants 404
- C4b 401
- C4B 403
 - variants 404
- C4B gene 401, 403
- C4-binding protein 428
- C4d 401, 402, 403
- CA19–9 *see* sialyl-Le^a
- Cad 136, 505, 507
 - GalNAc residues 507–9
 - malaria resistance 509
 - polyagglutination 519
 - red cell membrane 508
- Can 134–6
- cancer
 - ABC transporters in multidrug resistance 487, 489
 - CD99 expression 367
 - DARC association 317–18
 - diagnosis with sialyl-Le^a 58, 65–6
 - Ii antigens 474
 - p phenotype 173
 - see also* malignancy; named cancers and conditions
- carbon dioxide
 - membrane permeability 388
 - transport 345
- carbonic anhydrase II (CAII) 235–6, 345
- Cartwright system *see* Yt system
- cataract, congenital 472–3
- CBF/NF-Y transcription factor-binding motif 23–4
- CD15 *see* Le^x
- CD35 *see* CR1
- CD44 451
 - antibodies 450, 451
 - anti-In^b binding in fetal monocytes 452
 - AnWj 454, 503
 - functions 452
 - hyaluronan binding 452, 459
 - Indian antigens 449–50
 - In*(Lu) effects 268–9
 - proteoglycan 452
- CD44 gene 449, 450, 454

- CD47 194
 band 3 tetramer 345
 reduced expression in Rh_{null} and Rh_{mod} red cells 225
 Rh-deficiency syndrome 226
 CD55 508 *see* DAF
 CD55 gene 427, 428
 organisation **430**
 CD59 433–4
 malaria association 434
 CD75 269
 CD77 *see* P^k
 CD81 tetraspanin 367
 CD82 461, 464
 CD99 359, 362
 enzyme effects 362
 Ewing sarcoma 367
 function 367
 location 362
 non-human primates 367–8
 polymorphisms 365–6
 CD99 gene 363–5
 organisation **364**
 CD108 464
 CD151 461–2
 deficiency 463
 expression 463
 structure 462
 CD151 gene 461
 mutations 462
 CD176 516
 CD233 *see* AE1 red cell anion exchanger
 CD235A *see* glycophorin A (GPA)
 CD235B *see* glycophorin B (GPB)
 CD238 278
 CD239 259
 CD240CE *see* RhCcEe
 CD240D *see* RhD
 CD241 *see* RhAG
 CD242 *see* intercellular adhesion molecule 4 (ICAM-4)
 CDE notation 184–185
 CDR3 138
 ce 211
 cE 212
 Ce 211
 CE 211–12
 CEAG 219
 cell adhesion molecules *see* selectins
 Cellano *see* k
 CELO 204, 215
 ceMO 219
 CENR 218, 227
 CEST 218
 CFTR gene, KEL gene linkage 281
 C^G 208, 212, 214
 Ch 401–2
 phenotypes 404, **405**
 typing 402
 Ch1 400, 405, 406
 Ch2 400, 405, 406
 Ch3 400, 405, 406
 Ch4 400, 404, 405, **405**, 406
 Ch5 400, 404, 405, **405**, 406
 Ch6 400, 404, 405, **405**, 406
 chemokine receptors 314–315
 Chido/Rogers system 400–7
 antibodies 404–6
 antigenicity 405, 406
 antigens 1, 400–2
 location 401–2
 autoantibodies 406
 C4 coating of red cells 402
 complex polymorphisms 402–3
 disease associations 406–7
 phenotypes 402
 serology 400–1
 see also C4
 chimpanzee
 DARC homologues 309
 Kell phenotype 293
 see also non-human primates
 Chr^a **496–497**
 chromosomes 2
 blood group gene location 5, 6
 chronic granulomatous disease 295–6
 chronic lymphocytic leukaemia (CLL)
 alloanti-Jk^b 328
 i antigen 476–7
 chymotrypsin
 Kell antigen effects 292
 MNS antigen effects 106
 cisAB **42**, 43
 Cl^a **115**, 133
 clotting anomalies, ABO phenotype 67–8
 CO1 *see* Co^a
 CO2 *see* Co^b
 CO₂/O₂/NO channel 235–6
 Co3 384, **385**, 386
 Co4 384, **385**, 386–7
 CO gene 384
 Co^a 384, 385, **385**, **386**
 expression 387
 Co(a–b–) phenotype 384, 386–7
 Co^b 384, 385, **385**, **386**
 expression 387
 cold agglutination 469
 cold agglutinin(s) 469, 477–8
 anti-D IgM heavy chain variable region 230
 anti-I/anti-I^T 476
 Mycoplasma pneumoniae 475
 cold agglutinin disease 111, 469
 anti-i 475
 anti-M 137
 autoanti-I 474–5
 cold autoanti-LW 395
 cold lymphocytotoxins 474
 colon malignancy 65
 Sd^a association 508, 509
 colorectal carcinoma 519
 Colton system 384–8
 antibodies 387
 antigens 384, 385–7
 gene/genotype frequency 385, **386**
 glycoprotein 384, 385
 monosomy 7 387
 phenotype 384, 386
 polymorphism 385
 see also aquaporin-1 (AQP1)
 Co_{mod} phenotype 386
 complement, anti-D activation failure 229
 complement control protein (CCP)
 repeats 427–8, 429, 431, 432
 Knops system 439, 440, 442
 structure 441
 complement receptor type 1 *see* CR1
 complement regulatory glycoproteins 8
 concanavalin A lectin 269
 congenital cataract 472–3
 congenital dyserythropoietic anaemia (CDA) 386
 cryptantigens 519
 polyagglutination 519
 red cell CD44 deficiency 452
 type II 519
 contiguous gene deletion syndrome 296
 Co_{null} phenotype 386, 388
 COPII coat protein 519
Corynebacterium aquaticum 517
 Cosmc 518, 519
 COST1 *see* Cs^a
 COST2 *see* Cs^b
 Cost collection 439, 446
 coxsackievirus, DAF ligand 434
 CR1 428
 allotypes 439–40
 bacterial infections 445–6
 expression in pregnancy 445

- functions 445
 Knops antigens 439–42, 444
 malaria association 445
 CR1 gene 439
 location 440
 CR2 428
 Cr^a 428, 430–1
 CRAG 428, 432
 CRAM 428, 432
 Crawford 204
 CROM1 *see* Cr^a
 CROM2 *see* Tc^a
 CROM3 *see* Tc^b
 CROM4 *see* Tc^c
 CROM5 *see* Dr^a
 CROM6 *see* Es^a
 CROM7 *see* IFC
 CROM8 *see* WES^a
 CROM9 *see* WES^b
 CROM10 *see* UMC
 CROM11 *see* GUTI
 CROM12 *see* SERF
 CROM13 *see* ZENA
 CROM14 *see* CROV
 CROM15 *see* CRAM
 CROM16 *see* CROZ
 CROM17 *see* CRUE
 CROM18 *see* CRAG
 Cromer system 427–34
 antibodies 433
 antigens 427, 428, 430–3
 location 428
 serological characteristics 432–3
 monoclonal antibodies 433
 see also DAF
 Cromer-null phenotype 428–30
 CROV 428, 432
 CROZ 428, 432
 CRUE 428, 432
 cryptantigens 515
 congenital dyserythropoietic anaemia
 type II 519
 lectins 515, 516
 malignancy 518–19
 Tx 517
 Cs^a 439, 446
 Helgeson phenotype 446
 Cs(a–) phenotype 446
 Cs(a–) Yk(a–) phenotype 443–4
 Cs^b 439, 446
 C^w 212–13, 227
 C^x 212–13, 227
 cystic fibrosis
 ABC transporters 487
 CFTR gene *KEL* gene linkage 281
Cystisus sessilifolius 57
 cytoskeleton 8, 345, 346

 d 185
 D 182, 185, 194–6, 197–9, 200–7
 elevation 205
 epitopes 196, 197–9, 200
 structure 204–5
 expression 194
 fetal typing 206–7
 LW relationship 391, 394
 phenotype prediction from DNA
 206–7
 polypeptide 186
 site number on red cells 205
 variants 6–7, 182, 200–4
 clusters 203
 identification 205
 transfusion practice 205–6
 see also partial D
 D•• 217, 220–1
 D13 *see* Wr^a
 D14 *see* Wr^b
 D– phenotype 182, 189, 206–7, 237,
 394, 395
 haplotype 237
 molecular genetics 194–5
 transfusion practice 205, 206, 230
 D– – phenotype 217, 219–20
 D+ phenotype 237
 blood transfusion 232
 Rh mosaics 233
 D polypeptide 187, 188
 DAF 427–8, 431
 Cromer system antigen location 428
 deficiency 427
 Escherichia coli attachment 434
 functions 433–4
 malaria association 434
 monoclonal antibodies 433
 pathogenic microorganism receptor
 434
 placental trophoblast epithelial cells
 433
 structure 429
 viral infections 434
 DAK 200, 227
 DANE 116, 125–6
 Dantu 116, 129–30
 DAR 196, 197, 202, 203
 DARC 306–8
 absence from Fy(a–b–) cells 313
 cancer association 317–18
 chemokine binding 315
 distribution 314
 endothelial cells 315
 function on red cells 315
 HIV infection 317
 homologues 309
 non-human primates 309
 N-terminal amino acid sequence
 308, 316
 sickle cell disease 317
 structure 307
 DARC gene 306
 DARE 197, 202
 DAU 197
 Dav 220–1
 DBA 197
 DBT 197, 200, 202, 227
 Dc– 217, 221
 dCE haplotype 185
 DCE haplotype 213, 214
 DCE haplotype 207, 208
 DCS 197, 200
 DC^w– 217, 221–2
 decay-accelerating factor *see* DAF
 DEL 7, 194, 198, 204
 site number on red cells 205
 transfusion practice 206
 DFR 196, 198, 200, 202
 DFV 198
 DFW 198
 Dh^a 411, 417, 418–19
 DHAR 198, 200, 203–4, 227
 DHK 198
 DHMI 198
 DHO 198
 DHR 198
 DI1 *see* Di^a
 DI2 *see* Di^b
 DI3 *see* Wr^a
 DI4 *see* Wr^b
 DI5 *see* Wd^a
 DI6 *see* Rb^a
 DI7 *see* WARR
 DI8 *see* ELO
 DI9 *see* Wu
 DI10 *see* Bp^a
 DI11 *see* Mo^a
 DI12 *see* Hg^a
 DI13 *see* Vg^a
 DI14 *see* Sw^a
 DI15 *see* BOW
 DI16 *see* NFLD
 DI17 *see* Jn^a
 DI18 *see* KREP
 DI19 *see* Tr^a
 DI20 *see* Fr^a
 DI21 *see* SW1

- DI22 *see* DISK
- Di^a 336–40, **337**, 338, 343
 enzyme effects 338
 expression 338
 frequency 337, **340**
 reducing agent effects 338
- Di^b 336–40, **337**, 338, 343
 depression in South-East Asian
 ovalocytosis 347
 enzyme effects 338
 frequency 337
 reducing agent effects 338
 weak 338
- Diego system 336–47
 antigens 99, 336, **337**
 DI5 to DI22 343–4
 band 3 344
 deficiency 344–5
 membrane complexes 345–6
 tissue distribution 346
 molecular basis of polymorphism
 338, 339
see also Di^a; Di^b; Wr^a; Wr^b
- DII **197**, 200
- DIII **197**, 200–1
- DIM **198**
- disaccharides, precursor 14–15
- DISK 336, 339, **337**, **343**, 344
- distal renal tubule acidosis 345, 346
- DIV **197**, 200, 201
- DIV(C)– 217, 222
- DMH **198**
- DMI **198**
- DNA analysis 5–7
 ABO phenotype prediction 25
- DNA fingerprinting 3
- DNA repair diseases 140
- DNB **198**, 200
- DNU **198**, 200
- DO gene 376
- DO1 *see* Do^a
- DO2 *see* Do^b
- DO6 *see* DOYA
- DO7 *see* DOMR
- DO8 *see* DOLG
- Do^a 376, **377**, 377–8
 development/distribution 380
- Do^a/Do^b polymorphism 376
- Do^b 376, **377**, 377–8
 development/distribution 380
- DOL **198**
- DOLG 376, **377**, 380
- Dolichos biflorus* lectin 28–9, 30, 32, 55
 Cad antigen 505, 519
 Sd(a+++) 505, 506, 507, 519
- Dombrock system 376–81
 antibodies 380–1
 antigens 376, 377–80
 genotype 376, 377–8
 glycoprotein 376–7
 phenotype 376, 377, 379
- DOMR 376, **377**, 380
- Donath–Landsteiner (DL) antibodies
 169–70
- donor screening, molecular tests 7
- Do_{null} phenotype 379
- DOYA 376, **377**, 380
- Dr^a **428**, 431
- Dr(a–) phenotype 431
- DSLK 234
 absence from Rh_{null} red cells 225
- D^u 195–6
- Duclos 233–4
 absence from Rh_{null} red cells 225
- Duffy antigen receptor for chemokines
see DARC
- Duffy binding-like (DBL) family 421
- Duffy glycoprotein 306–8
 chemokine receptor function
 314–15
- Duffy system 306–18
 antigens 306, **307**, 314
 breast cancer 317–18
 malaria 315–17
 asthma 317
 erythroid silent allele (*see* *FY^uNull*
 gene, allele)
 genotype **308**, **309**
 determination 314
 Rh mosaics 232–3
- Duffy-binding-like (DBL) proteins
 141, 316
- DV **197**, 200, 201
- DVa **197**, 206
- DVI **197**, 200, 201–2, 205
 monoclonal anti-D for detection
 229
- DVII **197**, 202
- DVL **198**
- D^w 201, 227
- DWI **198**
- DYU **198**
- e 182, 185, 209–11
 sites on red cells 207, **208**
 variants 210
 transfusion practice 211
- E 182, 185, 209–11
 sites on red cells 209
 variants 209–10, 219
- EBA-175 141
- EBL-1 141
- echoviruses, DAF ligand 434
- ectoderm, ABH antigen expression 64,
 65
- E/e phenotype prediction from DNA
 209
- E/e polymorphisms **208**, 209
- EKH 219
- EKK 219
- EKLf erythroid transcription factor
 267, 386
- EKLf* gene mutations 164, 451
 i expression 470
 MER2 expression 463
- electrolytes, abnormal metabolism
 associated with *In(Lu)* 269
- elliptocytosis
 hereditary 421
 Leach phenotype 416
- ELO 339, **343**, 343–4
- Emm 502
 frequency **501**
- EMMPRIN 459
- En* allele, frequency 107–8
- En(a–) phenotype 98, 106–8
 biochemistry 108
 frequency 107–8
 malaria resistance 141
 molecular genetics 108
 serological characteristics of cells
 107
- En^a 106–108
- En^aFR 110
- En^aFS 109, 120
- En^aTS 109–110, 120
- ENAV 132
- ENDA 125–6
- endoderm, ABH antigen expression
 64, 65
- endothelins 293
- ENEH 126
- ENEP 132
- ENEV 132
- ENKT 127
- En(UK)* gene 123
- enzymes 8
- EPB41* gene 189
- Epstein–Barr virus (EBV), anti-i 475
- Er antigens 493–4
- Er1 *see* Er^a
- Er2 *see* Er^b
- Er3 493
- Er^a 493–4
- Er(a–) phenotype 493

- Er(a-b-) phenotype 493
 Er^b 493, 494
 ERIK 131
 ERMAP 371–2
 ERMAP gene 371–2
 mutations 373
 erythroblastic islands, LW 396
 erythroid cells, somatic mutation 140
 erythroid Krüppel-like factor *see* EKLF
 erythroid transcription factor
 erythroid membrane-associated protein
 see ERMAP
 erythropoiesis
 basigin role in erythropoietin-mediated 459
 CD151 463
 ICAM-4 296–297
 Kell glycoprotein 293
 Lu-gps 271–2
 LW 296–297
 MER2 463
 RhAG 193
 suppression by anti-K 284–285
 suppression by Gerbich alloantibodies 420
 Es^a 428, 430, 432
Escherichia coli 66
 DAF attachment site 434
 P antigen receptors 173
 red cell agglutination 142
Evonymus 56
 Evans 220–1, 227
 E^w 209, 227
 Ewing sarcoma, CD99 expression 367
 extracellular matrix metalloproteinase inducer (EMMPRIN) 459
- f 211
 Fabry disease 168
 Factor VIII 67, 68
 Fanconi anaemia 140
 Far 115, 133
 fetal D typing 206–7
 ficin, MNS antigen effects 106
 Fisher's synthesis 184–5
Fomes fomentarius 56
 FORS system 162–3
 FORS1 164, 165, 170
 Forssman glycolipid 162, 170
 FPTT 202, 227, 228
 molecular genetics 227
 FPTT-associated haplotypes 218
 Fr^a 339, 343, 343–4
 fucosidosis, Lewis antigens 68
 fucosyltransferase 12, 19, 20
 ABH secretors 19–20
 haemopoietic origin 21
 Lewis gene product 26
 see also FUT genes
 α 1,2-fucosyltransferase
 distal colon malignancy 65
 FUT gene control 43
 non-secretor levels 32
 α 1,3-fucosyltransferase 28
 α 1,4-fucosyltransferase 58
 FUT genes 28
 see also numbered FUT genes
 FUT1 12, 19
 ABH antigen genetic control in body 64, 65
 alleles 20, 43–4
 chromosome 19 13, 19
 H deficiency 43–44, 46
 isolation 19
 Lutheran locus linkage 262
 FUT2 12, 19
 ABH antigen genetic control in body 64, 65
 alleles 20, 44
 chromosome 19 13, 19
 interaction with FUT3 25
 Lutheran locus linkage 262
 mutation detection 21
 FUT3 12, 13
 ABH antigen genetic control in body 64
 alleles 26, 27, 28
 chromosome 19 13
 interaction with FUT2 25
 Lewis antigen 26
 Lutheran locus linkage 262
 FY gene 306, 307–8
 alleles 309
 frequencies 308
 FY1 *see* Fy^a
 FY2 *see* Fy^b
 Fy3 306, 307, 309, 312
 Fy4 307, 313
 Fy5 194, 306, 307, 309, 313
 Fy6 306, 307, 309
 non-human primates 313
 Fy^a 306, 307, 308–9
 development 314
 distribution 314
 enzyme effects 309
 frequency 308
 polymorphism 308–9
 site density 314
 Fy(a-b-) phenotype 306, 310, 311–13, 314
 African origin people 306, 311, 313
 HIV infection 317
 non-African origin people 311–12
 Plasmodium vivax infection 315–317
 sickle cell disease 317
 Fy^b 306, 307, 308–10
 development 314
 distribution 314
 enzyme effects 309
 frequency 308
 polymorphism 308–9
 site density 314
 FY^{Null} allele 308, 309, 311, 312, 313, 315, 316
 HIV infection 317
 Fy^x
 enzyme effects 309–10
 phenotype 310
 FY^x gene 306, 309–10
- G 212
 site density on red cells 212
 galactose (Gal) 12, 14–15, 16–17
 ABO biosynthesis 21
 li structure 471
 polyagglutination 518
 α -galactosidase A deficiency 168
 α 1,4-galactosyltransferase 167–8
 P1 synthesis 166
 GalNAc 12–17
 ABO biosynthesis 21
 acquired B phenomenon 517–18
 Cad 507–9
 li structure 471
 Sd^a 508
 Tn 518
 GalNAc-transferase 24
 Gal-transferase 24
 gastric cancer 173
 band 3 expression 346
 gastrointestinal cancer, Sd^a association 508, 509
 GATA1 gene 270–1
 Gb3 167, 168
 Gb4 *see* P antigen
 GBGT1 gene 170
 GBTG1 pseudogene 24
 GCNT2 gene 469, 470, 471, 474
 breast cancer metastasis 474
 late activation 477
 mutations 472–3
 transcript expression 474

- Ge2 410, 412–13
 development/distribution 420
 Ge:-2,3,4 phenotype 414–15
 Ge:-2,-3,4 phenotype 415–16
 Ge:-2,-3,-4 phenotype 416
 Ge3 410, 412, 413–14
 development/distribution 420
 Ge4 410, 412, 414
 GE5 *see* Wb
 GE6 *see* Ls^a
 GE7 *see* An^a
 GE8 *see* Dh^a
 GE9 *see* GEIS
 GE10 *see* GEPL
 GE11 *see* GEAT
 GE12 *see* GETI
 GEAT 411, 419
 GEIS 411, 417, 419
 gene conversion 119, 190–2, 403, 404
 genes, symbols 2, 4
 genomic DNA, ABO phenotype prediction 25
 GEPL 411, 419
 Gerbich system 410–21
 antibodies 414, 419–20
 antigens 412–19
 development/distribution 420
 autoantibodies 420
 Gerbich phenotype 410, 415–16
 Gerbich-negative phenotypes 414
 glycophorins 410–12
 Kell system association 416–17
 Leach phenotype 413, 416
 malaria 421
 monoclonal antibodies 420
 Rh system association 417
 serological history 412–13
 Vel antigen association 417, 502
 Yuso phenotype 410, 414–15
 GERW 411, 419
 GETI 411, 419
 GIL 485
 GIL- phenotype 485, 486
 Gill system 485–6
 glycoprotein 384
 Globo-A antigen 15
 Globo-H antigen 15
 globoside series 163, 164, 165
 P antigen 169
 globoside system 162–3, 169–70
 GLUT1 glucose transporter 345
Glycine soja 107, 139
 glycocalyx, components 8
 glycolipids 1, 9, 13
 glycophorin(s) 98–103, 410
 atypical glycosylation 134–6
 bacterial infections 142
 function 142–3
 gene evolution 143
 glycosylated extracellular domain 142–3
 hybrid 119–20, 121–2
 malaria 141, 142
 pathogen receptors 141–2
 viral infections 142
 glycophorin A (GPA) 96, 98, 99–101
 amino acid sequence 100–1, 103
 anion exchanger band 3 142
 band 3 membrane complex 341–2, 345, 346
 Cad red cells 507–8
 En(a-) cells lacking 108
 enzyme treatment effects 105–6
 evolution 142–3
 function 142–3
 gene coding for 101–3
 malarial parasite invasion 142
 monoclonal antibodies to non-polymorphic epitopes 110–11
 N-terminal peptides 103
 amino acid substitutions 113–14, 115–16, 116–18, 132
 red cell receptor for *Plasmodium falciparum* 346
 Rh_{null} red cells 225
 structure 99
 T activation 516
 virus receptor 143
 Wr^b expression association 342
 glycophorin A (GPA) deficiency phenotype 106–11, 142
 glycophorin B (GPB) 98, 99, 101
 amino acid sequence 101
 band 3 membrane complex 345, 346
 Cad red cells 507
 enzyme treatment effects 105–6
 evolution 142–3
 function 142–3
 gene coding for 101–3
 N-terminal peptides 103
 amino acid substitutions 113–14, 115–16, 116–18
 red cell receptor for *Plasmodium falciparum* 346
 structure 99
 T activation 516
 U antigen 112
 glycophorin B (GPB)-deficient phenotypes 111–13
 glycophorin C (GPC)
 BAEBL (VSTK) binding 421
 band 3 membrane complex 345, 346, 421
 Gerbich antigens 410–12, 413, 414, 420
 Gerbich-negative phenotype 414, 415
 Leach phenotype 416
 Ls^a 418
 membrane skeleton association 421
 receptor for *Plasmodium falciparum* 346, 421
 Wb antigen 417
 glycophorin D (GPD)
 An^a 418
 band 3 membrane complex 345, 346, 421
 Gerbich antigens 410–12, 413, 420
 Gerbich-negative phenotype 414, 415
 Leach phenotype 416
 Ls^a 418
 membrane skeleton association 421
 glycoposphatidylinositol (GPI) anchor 427, 429, 434
 glycoproteins 1, 8, 9, 13
 O-linked oligosaccharides 516, 517
 glycosidases, novel recombinant 50–1
 glycosphingolipids 13
 Lewis antigens 58–9
 NOR antigen 169
 glycosyltransferases 12, 17–18
 Bombay phenotype 45
 H deficient phenotypes 43–47
 upregulation in tumours 65–6
 Go^a 201, 227
 GP(A-B) hybrid 119, 121–2
 S antigen associated 120, 123
 GP(A-B-A).KI 127–8
 GP(A-B-A).Sat 128
 GP(A-B-A) hybrid 119, 121–2, 125–8
 GPA.N 110
 GP(B-A) hybrid 121–2, 129–31
 GP(B-A-B) hybrid 119, 121–2, 123–5, 341
 GP.Bun 118, 123, 124
 GP.Cal 131
 GP.Dane 118, 125–6
 GP.EBH 131
 GP.En(UK) 119
 GP.HF 118, 124
 GP.Hil 118, 119, 120
 GP.Hop 118, 123–4
 GP.Hut 118, 126–7

- GPI-linked glycoprotein 502
- GPJL **118**, 120
- GPJoh **118**, 127
- GP.Kip 124
- GP.Mar 131
- GP.Mur **118**, 120, 123, 124
- antibodies 125
 - biochemistry/molecular genetics 124–5
- GP.Nob **118**, 127
- GP.Sat 119
- GP.Sch 130
- GP.Vw **118**, 126–7
- GP.Zan 130–1
- GTA 21, 24–5
- cisAB phenotype 43
 - overlapping specificity with GTB 41–3
 - structure 24–5
- GTA₁ 29, 30
- GTA₂ 29, 30
- GTB 21, 24–5
- cisAB phenotype 43
 - B subgroups 38–9, 40
 - overlapping specificity with GTA 41–3
 - structure 24–5
- GUTI **428**, **430**, 432
- Gy^a 376, **377**, 378–9
- development/distribution 380
- Gy(a–) phenotype 379
- GYPA gene 98, 101–3
- chromosome location 103
 - En(a–) 108
 - misalignment with GYPB 119
 - mutations 143
 - non-human primates 143
 - promoter 103
 - structural organisation **102**
- GYPA mutation assay 140
- GYP(A–B) hybrid gene 108
- GYP(A–B)*Hil 120
- GYPA*Null 107
- GYPB gene 98, 101–3, 143
- chromosome location 103
 - En(a–) 108
 - He association 117
 - misalignment with GYPA 119
 - non-human primates 143
 - promoter 103
 - structural organisation **102**
- GYPB*Null 112–13
- GYPB(NY) gene 113
- GYPB-pseudoexon 119, 126, 128
- GYPC gene 410, 411–12, 414
- Gerbich phenotype 415–16
 - Leach phenotype 416
 - Ls^a 418
 - organisation 412
 - Yus phenotype 415
- GYPE gene 103, 143
- promoter 103
 - structural organisation **102**
- GYP*EBH 131
- GYP*He gene 125
- GYPHe(NY) gene 113
- GYP*Sch 130
- H antibodies 54–5
- H antigen 4, 12
- cisAB phenotype 43
 - biosynthesis 12, 19
 - body secretions 19–21
 - carbohydrate determinants 14–17
 - enzymatic degradation 50–1
 - human tissues 21
 - in plasma 33
 - secretion 31–3
 - structure 11–13, **15**
 - Type 1 structures 19, 21
 - Type 2 structures 19, 21
- H blood group, historical aspects 11–13
- haematological malignancy
- CD99 expression 367
 - Rh mosaicism 232, 233
 - see also* leukaemia; *named leukaemia diseases and conditions*
- haemoglobin 345–6
- haemolytic anaemia
- alpha-methyldopa-induced 140
 - Tn polyagglutination 518
 - VA polyagglutination 520
 - see also* cold agglutinin disease
- haemolytic disease of the fetus and newborn (HDFN) 3
- ABO antibodies 53
 - anti-At^a 502
 - antibodies to Rh low frequency antigens 227–8
 - anti-Co3 387
 - anti-Co^a 387
 - anti-D 182, 184, 230–1, 284–5
 - peptide immunotherapy 231
 - anti-D in women with variant D red cells 206
 - anti-Di^a 339
 - anti-Di^b 339
 - anti-Fy^a and -Fy^b 310
 - anti-Ge3 419–20
 - anti-Jk^a and -Jk^b 328
 - anti-Jr^a 488
 - anti-k 285
 - anti-K 282, 284–5
 - anti-LFAs 498
 - anti-M 137
 - anti-MAM 500, 503
 - anti-Mur 125
 - anti-N 137
 - anti-RHAG4 234
 - anti-S and -s 139
 - anti-U 140
 - anti-Vel 502
 - anti-Vw 127
 - anti-Wr^a 342
 - anti-Yt^a and anti-Yt^b 356
 - D evolution 237
 - fetal genotyping 5
 - D– pregnant women 206–7
 - K 282
 - low frequency antigens 495
 - prevention mechanism for ABO 477
 - Rh antigens 234
- haemolytic transfusion reaction (HTR) 3
- ABO 52–3
 - anti-AnWj 453–4
 - anti-At^a 502
 - anti-Bg 513
 - anti-Co3 387
 - anti-Co^a and -Co^b 387
 - anti-D 230
 - anti-Di^a and -Di^b 339
 - anti-Do^a and -Do^b 380–1
 - anti-Fy3 313
 - anti-Fy^a 310
 - anti-Fy^b 310–11
 - anti-Gy^a 381
 - anti-HLA 513
 - anti-Hy 381
 - anti-I 475
 - anti-In^b 452
 - anti-Jk3 330
 - anti-Jk^a and -Jk^b 328
 - anti-JMH 467
 - anti-Jr^a 488
 - anti-Js^b 287
 - anti-k 285
 - anti-K 284
 - anti-Ku 291
 - anti-Lan 490, 500
 - anti-LFAs 498
 - anti-M 137
 - anti-MAM 503

- In(Lu) 259, 267–70, 451–2
 abnormal red cell morphology and electrolyte metabolism 269
 AnWj 453, 502–3
 i expression 470
 MER2 expression 463
 molecular genetics 267, **268**
 osmotic fragility of cells 269
 phenotype 267–71
 variable effects 270
- integrins
 JMH system 467
 LW system 396–7
- intercellular adhesion molecule 1 (ICAM-1) 396
- intercellular adhesion molecule 2 (ICAM-2) 396
- intercellular adhesion molecule 3 (ICAM-3) 396
- intercellular adhesion molecule 4 (ICAM-4) 392–3, 396–7
 band 3 membrane complex 345, 346, 392–3
 LW antigens 392
- interleukin 8 (IL-8) 315
- International Society of Blood Transfusion (ISBT)
 gene symbols 4
 Rh numerical notation 185
 terminology 3, 5
- intestinal disorders, Inab phenotype 430
- intravenous immunoglobulin (IVIG) 53
- j 477
- JAHK 218, 227
- JAK2 tyrosine kinase 272
- JAL 217, 218, 227
- jaundice *see* neonatal jaundice
- Je^a **496, 497**
- JFV **496, 497**
- JK gene 325, 326, 329
 alleles and mutations 329, **330**
- JK1 *see* Jk^a
- JK^{01W.01} 330–1
- JK3 328–30
- JK2 *see* Jk^b
- Jk^a 325, 326–8
 development/distribution 327
 frequency 326, **327**
- JK^A
 allele responsible for Jk_{mod} phenotype 330–1
 genotype frequency 326, **327**
- Jk(a–b–) phenotype 325, 328–31
 JK alleles responsible **330**
 anti-Jk3 production 329–30
 dominant type 330
 frequency **329**
 transient 330
 urea lysis test 329
- Jk^a/Jk^b polymorphism 325, 326–7
- Jk^b 325, 326–8
 development/distribution 327
 frequency 326, **327**
- JK^B genotype frequency 326, **327**
- Jk_{mod} phenotype 330–1
- JMH system 465–7
 antigens 465–6, **467**
 glycoprotein 465
 variants 465, 466, **467**
- JMH1 465–6, **467**
 inheritance 466
- JMH2 466, **467**
- JMH3 466, **467**
- JMH4 466, **467**
- JMH5 466, **467**
- JMH6 466, **467**
- JMH– phenotype 465–6, 467
- JMHG *see* JMH4
- JMHK *see* JMH2
- JMHL *see* JMH3
- JMHM *see* JMH5
- JMHQ *see* JMH6
- Jn^a 339, **343**, 343–4
- Jo^a 376, **377**, 379–80
 development/distribution 380
- John Milton Hagen *see* JMH system
- JONES **496, 497**
- JR1 *see* Jr^a
- Jr^a 487, 488
 distribution 487
 frequency 487, **488**
- Jr(a–) phenotype 487, 488, 489
- Js^a 286–7
- Js^b 286–7
- Ju **477**, 478
- junctional complex 193, 346, 417
- Junior system 487–9
- k 281–5
 frequency 282
 unusual expression 283–4
- K 281–5
 fetal detection 282
 frequency 282, **283**
 genotyping 282–3
 unusual expression 283–4
- KALT *see* KEL29
- KANT *see* KEL33
- KASH *see* KEL34
- KCAM **440**, 444
- KEL gene 278
 chromosome location 281
 erythropoiesis 295
 linkage 281
 mutations 284
 organisation 280–1
- KEL1 *see* K
- KEL2 *see* k
- KEL3 *see* Kp^a
- KEL4 *see* Kp^b
- KEL5 *see* Ku
- KEL6 *see* Js^a
- KEL7 *see* Js^b
- KEL10 *see* UT^a
- KEL11 287–8
- KEL12 288
- KEL13 288
- KEL14 288
- KEL17 287–8
- KEL18 288
- KEL19 288–9
- KEL20 *see* Km
- KEL21 *see* Kp^c
- KEL22 289
- KEL23 289
- KEL24 288
- KEL25 289
- KEL26 289
- KEL27 289
- KEL28 289
- KEL29 289
- KEL30 289
- KEL31 289–90
- KEL32 290
- KEL33 290
- KEL34 290
- KEL35 290
- KEL36 290
- KEL37 290
- KEL38 289
- Kell antigen 278, **279**
 cells/tissues other than red cells 293
 depression in Gerbich-negative phenotypes 291–2
 enzyme effects 292–3
 frequency **283**
 reducing agent effects 292–3
 sites per red cell 280
 temporary loss 271
- Kell glycoprotein 280, 292, 293
 erythroid progenitor differentiation 285

- erythropoiesis 293
 expression on megakaryocytes 292
 extracellular domains 280
 Xk protein association 294–5
 Kell protein 280, 280, 293
 Kell system 278, **279**, 280–93
 evolution 293
 function 293
 Gerbich system association 416–17
 phenotype
 acquired depressed 292
 null 290–1
 transient depressed 292
 see also numbered KEL antigens
 KELP *see* KEL35
 KET1 *see* KEL36
 Kg **496**, **497**
 Kidd system 325–31
 antibodies 325
 glycoprotein 325–6
 UT-B red cell urea transporter 331
 kidney
 hereditary nephritis 463
 p phenotype 172
 urea transporters 331
 see also renal entries
 K/k genotyping 282
 K/k polymorphism 281–2
 KLF1 gene 267, **268**, 386
 mutations 259, 267, **268**, 270
 Km **296**
 K_{mod} 283–4, 291
 KN1 *see* Kn^a
 KN2 *see* Kn^b
 KN3 *see* McC^a
 KN4 *see* SI1
 KN5 *see* Yk^a
 KN6 *see* McC^b
 KN7 *see* SI2
 KN8 *see* SI3
 KN9 *see* KCAM
 Kn^a **440**, 441, 442
 Kn^b **440**, 442
 Knops system 439–46
 antibodies 444–5
 antigens 428, 439, **440**, 440–1, 442–4
 expression 444
 serological characteristics 444
 bacterial infections 445–6
 CR1 439–42, 445
 Helgeson phenotype 441–2, 444
 Cs^a 446
- K_o
 phenotype 285, 290–1
 Xk protein 294
 Kp^a 285–6
 effect 291
 Kp^b 285–6
 Kp^c 286
 KREP 339, 343–4
 KTIM *see* KEL30
 KUCI *see* KEL32
 KUHL *see* KEL37
 Kx antigen 278, 295, **296**
 Kx system 293–6
 KYO *see* KEL31
 KYOR *see* KEL38
- Laburnum alpinum* 57
 lactosylceramide 165
 LADII **44**, 47
 Lan 487, 489–90
 frequency 489
 LAN1 *see* Lan
 Lan– phenotype 490, 491
 Langeris system 487, 489–91
 Lan-weak phenotype 489–90
 le allele 26
 Le allele 26
 Le gene 26
 frequency 60
 Le^a 12, 57–9
 ABH non-secretors 26
 development 59
 expression 15
 frequency 59–60
 plasma 58
 pregnancy 59
 red cells
 frequency 59–60
 uptake by 58–9
 secretions 57–8, 60
 structure **14**
 Le^{abx} 62
 Le^b 12, 57–9
 development 59
 expression 15
 frequency 60
 plasma 58
 pregnancy 59
 red cells
 frequency 60
 uptake by 58–9
 secretions 57–8, 60
 structure 11–13, 13–17
 Type 1 structures 16
 Lewis system 57–63
 historical aspects 11–13
- Le^d 13, 62
 structure **14**
 Le^x
 CD15 28, 63
 see also Le^{abx}
 Le^y 28, 63
 Leach phenotype 413, 416
 lectins 55–7
 anti-A 55–6
 anti-B 56
 anti-I 475
 anti-M 138–9
 anti-N 138–9
 anti-Sd^a 505, 506, 507, 519
 cryptantigens 515, **516**
 En(a–) cell reactions 107
 polyagglutination 515, 516, 517, 518, 519, 520
 Lepore hybrid glycoporphin 119, 123
 Le-transferase 26
 leucocyte adhesion deficiency type II (LADII) **44**, 47
 leucocytes, ABH and Lewis antigen expression 63–4
 leucopenia, Tn polyagglutination 518
 leukaemia
 i antigen 476–7
 Tn polyagglutination 519
 see also named leukaemia conditions and diseases
 Lewis antibodies 60–2
 clinical significance 61
 renal transplantation 61–2
 Lewis antigen 1, 25–6, **27**, 28
 biosynthesis 11–13, 26
 development 59
 expression
 on ectodermal/endodermal/mesodermal tissues 64
 on leucocytes 63–4
 on platelets 64
 on tumours 65–6
 frequency 59–60
 fucosidosis 68
 glycoconjugates 13–14
 molecular genetics 26, **27**, 28
 pregnancy 59
 red cells
 frequency 59–60
 uptake by 58–9
 secretions 57–8, 60
 structure 11–13, 13–17
 Type 1 structures 16

- Li 477, 478
 Li^a 496–7, 497
 LKE 165, 170–1
 biochemistry/biosynthesis 171–2
 LOCR 218–19, 227
Lotus tetragonolobus 56, 57
 low frequency antigens (LFAs) 4,
 495–8
 antibodies 495–6, **497**
 clinical significance 498
 frequencies 495, **496**
 Ls^a 417–18
 LU gene 259
 chromosome location 262
 exon/intron organisation 260, **261**
 organisation 261–2
 LU1 *see* Lu^a
 LU2 *see* Lu^b
 Lu3 267
 Lu4 **260**, 265
 Lu5 **260**, 265
 Lu6 **260**, 263, 264
 Lu7 **260**, 263, 265
 Lu8 **260**, 263, 264
 Lu9 **260**, 263, 264
 Lu11 **260**, 263, 265
 Lu12 265
 Lu13 265
 Lu14 **260**, 263, 264
 Lu16 265–6
 Lu17 266
 LU18 *see* Au^a
 LU19 *see* Au^b
 Lu20 266
 Lu21 266
 LU22 *see* LURC
 Lu^a 262–3
 Lu(a–b–) 270
 acquired phenotypes 271
 see Lu_{mod} and Lu_{null}
 Lu^b 262–3
 Lud 477, 478
 Lu-gps 259–62
 disease associations 272
 distribution 271
 erythropoiesis 271–2
 functions 271–2
 isoforms 271
 laminin binding capacity 271
 structure 261
Lumbricus terrestris 165
 Lu_{mod} 267–71
 KLF1 mutations **268**
 In(Lu) phenotype 267–70, 451, 452
 X-linked 270–1, 451, 452
 Lu_{null} 259, 266–7
 LURC 266
 Lutheran locus 5, 262
 Lutheran system 259–72
 antibodies 264
 antigens 259, **260**
 enzyme effects on antigens 266
 glycoproteins 259–62
 disease associations 272
 distribution 271
 functions 271–2
 recombinant antigens 266
 reducing agent effects on antigens
 266
 sickle cell disease 272
 terminology 3, 4
 LW gene 392
 LW system 184, 391–7
 acquired negative phenotype 394–5
 antibodies 395–6
 animal 396
 antigens 391, 392, 393
 non-human primates 397
 autoantibodies 395–6
 band 3 membrane complex 346
 D antigen relationship 391, 394
 development 394
 disease association 396–7
 expression 394
 functions 396–7
 glycoprotein 193, 392–3, 393
 integrins 396–7
 red cell senescence 396–7
 sickle cell disease 272, 397
 transient antibodies 395
 LW5 *see* LW^a
 LW6 *see* LW^{ab}
 LW7 *see* LW^b
 LW^a 391, 393, 394
 enzyme/reducing agent effects 394
 LW^{ab} **392**, 393–4
 enzyme/reducing agent effects 394
 LW(a–b–) phenotype 393–5
 LW^a/LW^b polymorphism 392, 393
 LW^b 391, **392**, 393
 enzyme/reducing agent effects 394
 M 96, 103–4
 amino acid groups **103**, 104
 frequency 104
 gene frequency 104
 genotype frequency **105**
 inheritance 105
 phenotype frequency 104
 polymorphisms 103–4
 sialic acid 104
 variants 113–14, **115–16**, 116–18
 M₁ 134–6
 biochemistry 136
 genetics 135
 serology 135
Maclura aurantiaca 139
 malaria 67
 basigin role 459
 Cad family resistance 509
 CD55 levels 434
 CD59 levels 434
 CRI association 445
 Duffy antigens 315–17
 Gerbich antigens 421
 glycophorins 141, 142
 McC^a and McC^b association 445
 protection with South-East Asian
 ovalocytosis 346–7
 resistance with Fy(a–b–) phenotype
 306
 Sd(a+++)
 cell resistance 509
 see also Plasmodium
 malignancy
 A antigen incompatibility 66
 B-CAM 272
 CD99 expression 367
 cryptantigens 518–19
 distal colon 65
 li antigens 474
 verotoxins 173
 Vg^a 339, **343**, 343–4
 see also cancer; haematological
 malignancy; *named malignancies*
 and conditions
 MAM 503
 MAR 213
 MARS 132
 matrix metalloproteinases (MMPs)
 459
 matrix-assisted laser desorption/
 ionisation time-of-flight
 (MALDI TOF) mass
 spectrometry 7
 fetal K detection 282
 M^c 114, 116
 McC^a **440**, 441, 442–3
 malaria association 445
 McC^b **440**, 442–3
 malaria association 445
 McLeod phenotype 292, 295
 immune response 296
 McLeod syndrome 278, 294, 295
 inheritance/molecular genetics
 295–6

- MCT1 and MCT4 459
 Me 477, 478
 M^c 117
 membrane inhibitor of reactive lysis
 (MIRL) *see* CD59
 membrane transporters 7–8
 membrane-palmitoylated protein 1
 (MMP1) 421
 MER2 269, 461, 462–3
 enzyme effects 462
 quantitative polymorphism 462–3
 reducing agent effects 462
 mesoderm, ABH antigen expression
 64, 65
 metastases, T and Tn cryptantigens
 519
 M⁸ 113–14, 115
 M-Hyde Park haemoglobin 519
 Mi.I *see* GP.Vw
 Mi.II *see* GP.Hut
 Mi.III *see* GP.Mur
 Mi.IV *see* GP.Hop
 Mi.V *see* GP.Hil
 Mi.VI *see* GP.Bun
 Mi.VII *see* GP.Nob
 Mi.VIII *see* GP.Joh
 Mi.IX *see* GP.Dane
 Mi.X *see* GP.HF
 Mi.XI *see* GP.JL
 Mi^a 129
 β₂-microglobulin 513
 Milne 496, 497
 Miltenberger series 117–18
 MINY 128
 Mit 116, 134
 mitogen-activated protein kinase
 (MAPK) pathway 467
 M^k gene 98, 108–9
 biochemistry/molecular genetics
 109
 M^k phenotype 108–9
 antibodies produced by 110
 M-like alloantibodies 137
 MN antibodies 116–17
 MNS antigens 96, 97, 98
 development 142
 distribution 142
 enzyme treatment 105–6
 frequency 104–5
 gene frequency 104–5
 inheritance 105
 polymorphisms 103–5
 MNS system 96–143
 biochemistry 98–103
 genotype 96, 98
 glycophorin A-deficient phenotypes
 106–11
 glycophorins
 with atypical glycosylation 134–6
 evolution 142–3
 function 142–3
 hybrid 119–20, 121–2, 128–9
 as pathogen receptors 141–2
 structure 99
 GPA amino acid substitutions 132
 GP(A–B) variants 120, 121–2, 123
 GP(A–B–A) variants 121–2, 125–8
 GP(B–A) variants 121–2, 129–31
 GP(B–A–B) variants 121–2, 123–5
 GPB-deficient phenotypes 111–13
 GYPA mutation assay 140
 low frequency antigens 132–4
 molecular genetics 98–103
 phenotype 96, 98
 frequency 104–5
 polymorphisms 103–5
 Rh association 140–1
 U antigen 111–13
 MNS1 *see* M
 MNS2 *see* N
 MNS3 *see* S
 MNS4 *see* s
 MNS5 *see* U
 MNS6 *see* He
 MNS7 *see* Mi^a
 MNS8 *see* M^c
 MNS9 *see* Vw
 MNS10 *see* Mur
 MNS11 *see* M⁸
 MNS12 *see* Vr
 MNS13 *see* M^c
 MNS14 *see* Mt^a
 MNS15 *see* St^a
 MNS16 *see* Ri^a
 MNS17 *see* Cl^a
 MNS18 *see* Ny^a
 MNS19 *see* Hut
 MNS20 *see* Hil
 MNS21 *see* M^v
 MNS22 *see* Far
 MNS23 *see* s^D
 MNS24 *see* Mit
 MNS25 *see* Dantu
 MNS26 *see* Hop
 MNS27 *see* Nob
 MNS28 *see* En^a
 MNS29 *see* ENKT
 MNS30 *see* 'N'
 MNS31 *see* Or
 MNS32 *see* DANE
 MNS33 *see* TSEN
 MNS34 *see* MINY
 MNS35 *see* MUT
 MNS36 *see* SAT
 MNS37 *see* ERIK
 MNS38 *see* Os^a
 MNS39 *see* ENEP
 MNS40 *see* ENEH
 MNS41 *see* HAG
 MNS42 132
 MNS43 *see* MARS
 MNS44 *see* ENDA
 MNS45 *see* ENEV
 MNS46 *see* MNTD
 MNTD 116, 134
 Mo^a 339, 343, 343–4
Mollucella laevis 139
 monocarboxylate transporters (MCT)
 459
 monosomy 7 387
 MSP1 346
 Mt^a 115, 133
 MTP 503
 multidrug resistance, ABCG2 487, 489
 Mur 115, 118, 128
 MUT 127
 M^v 115, 133
Mycoplasma pneumoniae
 anti-I 469
 autoanti-I 475
 cold agglutinins 475
 myelodysplastic syndrome 517, 519
 myeloid leukaemia
 Rh mosaicism 232
 see also acute myeloid leukaemia
 (AML)
 N 96, 137
 amino acid groups 104
 frequency 104
 gene frequency 104
 genotype frequency 105
 inheritance 105
 phenotype frequency 104
 polymorphisms 103–4
 sialic acid 104
 variants 113–14, 115–16, 116–18
 'N' 101
N-acetylgalactosamine *see* GalNAc
 necrotising enterocolitis 516–17
 nephritis, hereditary, anti-MER2
 463
 neuroacanthocytosis 278
 see also McLeod syndrome
 NFLD 339, 343, 343–4

- NH₃/NH₄⁺ transporter 235
 900 series 5, 500
 901 series 500, **501**
 NO channel 236
 Nob **116**, 118
 non-Hodgkin's lymphoma, mimicking
 autoanti-Co3 387
 non-human primates
 ABO genes 24
 DARC homologues 309
 Fy6 313
 GYPA and GYPB genes 143
 Ii antigens 474
 Kell phenotype 293
 LW antigen 397
 RH genes 237
 Xg^a 367–8
 NOR **164**, 165, 168–9
 polyagglutination 519
 Norovirus 66–7
 Nou 222
 Ny^a **115**, 133

 O alleles 22, 23
 261delG 24
 evolution 23, 24
 frequency 30, **31**
 non-deletion 22, 23, 38
 O blood group
 anti-A,B serum 52
 bacterial infections 66
 malaria 66
 O^I 22, 23
 O^{Iv} 23
 O² 22, 23, 38
 O₂ channel 236
 O_h phenotype *see* Bombay phenotype
 O_h-secretor **44**, 46
 Ok system 457–9
 antibodies 458
 antigens 457–8
 OK1 *see* Ok^a
 OK2 457, 458
 OK3 457, 458
 Ok^a 457, **458**
 OKGV *see* OK2
 OKVM *see* OK3
 Ol^a 234
 Om **477**, 478
 Or **116**, 134
 Os^a **116**, 134
 osteocarcinoma, CD99 expression
 367
 oxygen channel 236
 oxygen transport 345

 P1 162, 163–7
 biochemistry/biosynthesis 165,
 165–6
 development 164, 165
 distribution 165
 frequency 163–4
 inheritance 164
 In(Lu) effects 268, 269
 sources 165
 strength variation 164
 structure **164**, 166
 P1PK system 162–7
 P1K1 *see* P1
 P1PK3 *see* P^k
 P1PK4 *see* NOR
 p55 421
 P antigen 163, 165, 169
 biochemistry/biosynthesis **164**, 165,
 169
 pathogenic micro-organism receptors
 173–4
 p phenotype 171–3
 antibodies 172–3
 biochemical effects 172
 cancer 173
 frequency 172
 habitual spontaneous abortion 174
 inheritance 172
 molecular genetics 172
 P synthetase 172
 PABIX gene 363, 364
 pancreatic cancer, ABO phenotype 68
 papain, MNS antigen effects 106
 PAR1 and PAR2 363
 para-Bombay phenotype 19
 paragloboside 163, **164**, 166, 470
 series 163, **164**, 165
 PARG **226**
 paroxysmal cold haemoglobinuria
 169–70
 paroxysmal nocturnal haemoglobinuria
 (PNH) and PNHIII cells
 CD59 deficiency 433–4
 DAF (Cromer) deficiency 427, 434
 Dombrock 376
 Emm 502
 JMH 465
 PIGA mutations 434
 Yt 354
 partial D 195–6, **197–9**, 200
 parvovirus B19 173–4
 passenger lymphocyte syndrome 53–4
 pegylation 51
 PEL 503
 PEPC gene 189

 PflRh5 459
 Phaseolus vulgaris 139
 Phlomis fruticosa 56
 PIGA gene mutations 434
 pigeon excrement 165
 PIP gene, KEL gene linkage 281
 P^k 162, 163
 biochemistry/biosynthesis 167–8
 expression 168
 HIV infection protection 174
 phenotype 167
 structure **164**
 verotoxins 173
 Plasmodium falciparum
 ABO 67
 band 3 346
 basigin 459
 CD55 levels 434
 CRI association 445
 DAF levels 434
 Duffy binding-like (DBL) family
 421
 Gerbich antigens 421
 glycophorins 141, 142, 421
 neoantigen exposure in infected red
 cells 346
 Sd(a+++)⁺ cell resistance 509
 var genes 316
 Plasmodium falciparum merozoite
 surface protein 1 (MSP1)
 346
 Plasmodium knowlesi 316
 Plasmodium vivax 306, 313, 315–17
 platelets, ABH and Lewis antigen
 expression and incompatibility
 64
 Plexin C1 467
 pneumococcal infection 517
 haemolytic uremic syndrome 516
 polyagglutination 168–9, 515–20
 acquired 515–19
 acquired B 517–18
 Cad 519
 classification 515, **516**
 congenital dyserythropoietic anaemia
 type II 519
 definition 515
 Hyde Park **516**, 519–20
 inherited **516**, 519–20
 lectins 515, 516, 517, 518, 519,
 520
 microbial 515–18
 non-microbial 518–19
 NOR 519
 Sd^a **516**, 519

- T 515–17, 518–19
 Th 517
 Tk 517, 518–19
 Tn **516, 517**, 518–19
 Tr **516**, 520
 undetermined **516**, 520
 VA 520
 polycythemia vera, Lu-gps 272
 polyethylene glycol (PEG), antigen
 expression modification 51
 polyglycosylceramide 470
 polymerase chain reaction (PCR) 7
 porphyrin transporter 489, 490–1
 Pr antigens 111, 477
 pregnancy
 CR1 expression 445
 Indian antigens 451
 Lewis antigens 59
 Sd^a 506
 preimplantation genetic diagnosis, K
 282–3
 preleukaemic dysmyelopoietic
 syndromes 387
 pronase, MNS antigen effects 106
 prostate cancer
 Duffy 317
 CD99 expression 367
 proteases, MNS antigen effects
 105–6
 pseudoautosomal boundary 363, 364
 XGR gene 364, 366
 pseudoautosomal region 363
 Pt^a 496–7, **496, 497**
Ptilota plumosa 56
 PX2 antigen **164**, 165, 171, 173

 Radin *see* Rd
 Raph system 461–4
 antibody 462, 463
 antigen 461–3
 glycoprotein 461–2
 RAPH1 *see* MER2
 RASM **496, 497**
 RAZ *see* KEL27
 Rb^a 339, **343**, 343–4
 RCCX genetic unit 404
 Rd 371, **372**, 373–4
 enzyme effects 373
 frequency 373, **374**
 Re^a **496, 497**
 receptors 8
 regulator of complement activation
 (RCA) gene cluster 428
 REIT **496, 497**
 renal dialysis, anti-N 137–8
 renal transplantation
 autoanti-Jk^b 328
 Duffy mismatched 310
 Lewis antibodies 61–2
 renal tubule acidosis, distal 345, 346
 respiratory gas transport 345
 reticulosis, autoanti-i 475
 Réunion O_h phenotype 45
 anti-H 54
 Rg 401–2
 phenotypes 404, **405**
 typing 402
r^G gene 212, 218
 Rg1 400
 Rg2 400
 Rh antibodies 228–32
 autoantibodies 232
 enzyme only 231–2
 IgM, cold agglutinin activity 476
 transplant donor-derived 232
 see also anti-Rh
Rh boxes 191, 207
 Rh genes
 chromosomal assignment 189–90
 cloning 187–8
 non-human primates 237
 Rh system 182, **183**, 184–96, **197–9**,
 200–15, **216**, 217–33, 234–7
 acquired phenotype changes 232–3
 antigens **183**
 band 3 complex 193, 346
 development/distribution 234
 enzyme-only antibodies 231–2
 evolution 236–7
 Fisher's synthesis 184–5
 functional aspects 234–6
 genetic models 184–6
 genotypes 186, **187**
 Gerbich system association 417
 haplotypes 182, 184, **185**, 186, 237
 historical aspects 184
 HOFM association 497
 low frequency antigens 226–8
 MNS system association 140–1
 mosaics 232–3
 notation 184–6
 phenotypes 186, **187**
 polypeptides 186–94
 identification/isolation 186
 Tippett's two-locus model 185–6
 Wiener's theory 185
 see also C; c; D; E; e
 RH1 *see* D
 RH2 *see* C
 RH3 *see* E
 RH4 *see* c
 RH5 *see* e
 RH6 *see* ce
 RH7 *see* Ce
 RH8 *see* C^w
 RH9 *see* C^x
 RH10 *see* V
 RH11 *see* E^w
 RH12 *see* G
 RH17 *see* Hr_o
 RH18 *see* Hr
 RH19 *see* hr^s
 RH20 *see* V
 RH21 *see* C^G
 RH22 *see* CE
 RH23 *see* D^w
 Rh26 218–19
 RH27 *see* cE
 RH28 *see* hr^H
 RH29 *see* 225
 RH30 *see* Go^a
 RH31 *see* hr^B
 Rh32 202, 227, 228
 Rh33 203–4, 227
 RH34 *see* Hr^B
 Rh35 218, 227
 RH36 *see* Be^a
 RH37 *see* Evans
 RH40 *see* Tar
 Rh41 211
 Rh42 227
 RH43 *see* Crawford
 RH44 *see* Nou
 RH45 *see* Riv
 RH46 215, 217
 RH47 *see* Dav
 RH48 *see* JAL
 RH49 *see* STEM
 RH50 *see* FPTT
 RH51 *see* MAR
 RH52 *see* BARC
 RH53 *see* JAHK
 RH54 *see* DAK
 RH55 *see* LOCR
 RH56 *see* CENR
 RH57 *see* CEST
 RH58 *see* CELO
 RH59 *see* CEAG
 RH60 *see* PARG
 RH61 *see* ceMO
 RhAG 192–3, 192, 233–4
 band 3 complex 193, 345, 346
 cation transport 236
 CO₂/O₂/NO channel 235–6
 development/distribution 234

- $\text{NH}_3/\text{NH}_4^+$ transporter 235
 protein function aspects 234–6
 reduced expression in Rh_{null} and Rh_{mod} red cells 225
RHAG gene 184, 192, 193
 evolution 236–7
 genomic organisation 190, 192–3
 mutations 193, 223
 Rh_{mod} 224–5
 Rh_{null} regulator type 223, 224
RHAG system 233–4
 antigens 233
RHAG1 see *Duclos*
RHAG2 see O1^a
RHAG3 see *DSLK*
RHAG4 234
 Rh-associated glycoprotein see *RhAG*;
 RHAG system
RhBG 193
RHBG gene 236
RHCE gene
 cloning 187, 188
 evolution 237
 exons 190, 191
 genomic organisation 190, 191
 genomic rearrangement 190–1, 192
RhCE polypeptide 186, 188, 189, 191
 G reactivity 212
*RHCE*ce* gene, variant alleles 216, 219
*RHCE*Ce* gene,
 variant alleles 215, 216, 217–18
*RHCE*ce* gene, variant alleles 216,
 218–19
 encoding epitopes of D 203–4, 219
*RHCE*ceAG* 216, 219
*RHCE*ceAR* gene 202, 215, 216, 219
*RHCE*ceBE* gene 216, 219
*RHCE*ceBI* 216, 219
*RHCE*ceEK* 216, 219
*RHCE*ceHAR* 216, 219
*RHCE*CeIAHK* gene 216, 218
*RHCE*ceJAL* gene 216, 218
*RHCE*CeJAL* gene 216, 217
*RHCE*ceLOC* gene 216, 218–19
*RHCE*ceMO* 216, 219
*RHCE*CeNR* 216, 217, 218
*RHCE*ceRA* gene 216, 219
*RHCE*CeRN* 215, 216, 217
*RHCE*ceRT* 216, 219
*RHCE*ceSL* 216, 219
*RHCE*CeVA* gene 216, 218
*RHCE*ceVS* 216, 219
*RHCE*E* gene 209
RhCG 193
RHCG gene 236
RhD polypeptide 186–9, 188, 189,
 191
RHD gene
 cloning 187, 188
 D– phenotype 194–5
 prediction 206
 D variant encoding 194–206
 evolution 237
 exons 190, 191
 fetal screening 207
 G reactivity 212
 genomic organisation 190, 191
 genomic rearrangement 190–1,
 192
 zygosity testing 207
RHD pseudogene (*RHDψ*) 194–5
RHD–CE(2–9)–D_s gene 195
RHD–CE–D^s gene 195, 208, 209
 Rh-deficiency phenotypes 222–6
 Rh-deficiency syndrome 225–6
 rheumatoid arthritis 513
 Rh_{mod} 223, 224–5, 225–6
 Rh_{null} 184, 222–4, 225–6
 amorph type 222, 223–4
 antibodies in sera 225
 regulator type 223, 224
 Rh-deficiency syndrome 225–6
 Ri^a 115, 133
Riv 222, 227
 R^N 215, 217
 R_0^{Har} 203–4, 217, 219, 227
 rotaviruses 67
 routine antenatal anti-D prophylaxis
 (RAADP) 230
Rx 477

s antigen
 frequency 104–5
 genotype frequency 105
 inheritance 105
 polymorphisms 104
S antigen 96, 98
 frequency 104–5
 genotype frequency 105
 GP(A–B) hybrid association 120,
 123
 inheritance 105
 polymorphisms 104
Sa 111, 477
SARA 496, 497
SAT 116, 123
SC1 371, 372, 372–3
 enzyme effects 373
SC2 371, 372, 372–3
 enzyme effects 373
 frequency 372–3
SC3 371, 372, 373
SC4 see *Rd*
SC5 372, 374
SC6 372, 374
SC7 372, 374
SCAN see *SC7*
SCER see *SC6*
Scianna system 371–4
 glycoprotein 371–2
SC_{null} phenotype 373
 s^D 116, 134
 Sd^a 505–6
 babies 506
 biochemistry 507, 508, 508
 body fluids 506
 colon malignancy association 508,
 509
 frequency 505, 506
 gastrointestinal cancer association
 508, 509
 inheritance 506
 malaria 509
 polyagglutination 516, 519
 pregnancy 506
 red cells 507–8
 Tamm–Horsfall protein association
 507
 tissues 506
 urine 507
 Sd(a+++) 505–6, 507
 polyagglutination 516, 519
 Sd^a glycosyltransferase 508
 Sd^a -transferase 509
se allele 32
Se allele 32
Se gene 26
Se/se alleles 20
SEC1 pseudogene 20–1
SEC23B gene 519
Secretor gene see *FUT2*
 selectins 28, 47, 63, 64, 65, 68
Sema7A 465, 466
 expression 466, 467
 functions 467
SEMA7A gene 465, 466
 semaphorins 465
 senescent red cells
 band 3 345, 346
 LW 396
SERF 428, 430, 432
 700 series 4, 495, 496

- Se^w 20, 32–3
 sex chromosomes 359
 aneuploidy 366–7
 Sext 135, 136
 Shiga toxin 173
Shigella dysenteriae 173
 SHIN 496–7
 SL1 440, 441, 443
 SL2 440, 443
 SL3 440, 443
 Sia-b1 477, 478
 Sia-l1 477, 478
 Sia-lb-1 and -2 477, 478
 sialic acid
 glycophorin glycosylated extracellular domain 142–3
 Plasmodium falciparum invasion of red cells 141
 sialidase
 bacterial 516
 MNS antigen effects 106
 sialoglycoproteins *see* glycophorin(s)
 sialosylparagloboside 164, 165, 171
 Sd^a phenotype association 508
 sialyl-Le^a 65, 68
 cancer diagnosis 58, 65–6
 Sd^a expression 509
 structure 14
 sialyl-Le^x 28, 63, 65, 68
 Sd^a expression 509
 sialyl-Tn 517, 518–19
 sickle cell disease
 anti-Fy5 313
 anti-Jo^a 381
 Duffy antigens 317
 Duffy genotyping 314
 Hr and Hr^b 219
 Lu 272
 LW 272, 397
 transfusion 211
 Sid 505–9
 antibodies 507
 see Sd^a
 single chain FV (scFv) antibody
 fragments 229
 Sj 134–6
 biochemistry/genetics 136
 SLC4A1 gene 336, 506
 organisation 338
 SLC14A1 gene 325, 326
 bladder cancer susceptibility 331
 SLC14A2 gene 326
 Sm *see* SC1
Sophora japonica 107, 139
 South-East Asian ovalocytosis 346–7
 Di^b depression 338
 I^T expression 476
 spherocytosis, hereditary 272
 squamous cell carcinoma, B-CAM 272
 SS red cells 272
 SSEA-4 murine stage-specific
 embryonic antigen 171
 St^a 130–1, 115
 STAR *see* SC5
 STEM 211, 227
 stomatocytes 226
 SW1 339, 343–4
 Sw^a 339, 343, 343–4
 systemic lupus erythematosus (SLE)
 Ch/Rg-null phenotype 406
 HLA red cell expression 513
 T activation 515–17
 T antigen 136
 structure 15, 517
 T cells, CD81 tetraspanin web 367
 T polyagglutination 515–17, 518–19
 Tamm–Horsfall protein, Sd^a association 507
 Tar 202, 220, 227
 Tc^a 428, 430, 431
 Tc(a–b–) phenotype 431
 Tc^aTc^b 431
 Tc^b 428, 431
 Tc^c 428, 430
 testicular disorder of sex development 366
 tetraspanin superfamily (TM4SF) 461, 464
 functions 463
 tetraspanin web 367, 463
 Th polyagglutination 517
 β-thalassaemia minor, CD151
 deficiency 463
 thrombocytopenia, Tn
 polyagglutination 518
 Tippet's two-locus model 185–6
 Tk polyagglutination 517, 518–19
 Tm 134–6
 biochemistry/genetics 136
 Tn 136
 polyagglutination 516, 517, 518–19
 structure 517
 To^a 496, 497
 TOU *see* KEL26
 Tr polyagglutination 516, 520
 Tr^a 339, 343, 343–4
 transfusion *see* blood transfusion
 transfusion-associated lung injury 317
 transplantation
 ABO antigens 53–4
 hyperacute rejection 53
 Lewis antibodies 61–2
 see also renal transplantation
 trypsin
 Kell antigen effects 292
 MNS antigen effects 105–6
 TSEN 123, 128
 TSPAN24 *see* CD151
 TSPAN27 *see* CD82
 T-synthase 518, 519
 tumour-associated carbohydrate
 antigens 65
 tumours
 ABH antigen expression 64–6
 Lewis antigen expression 65–6
 turtle dove ovomucoid 165
 twin chimeras 59
 Tx cryptantigen 517
 Type 1 H *see* Le^d
 U 111–13
 biochemistry 112
 frequency 113
 molecular genetics 112–13
 UI^a 287
Ulex europaeus 56, 57
 U-like autoantibodies 140
 UMC 428, 430, 432
 unequal crossing-over 119, 403–4
 uric acid transporter 489
 uromodulin 507, 508
 UT-A urea transporter 331
 UT-B red cell urea transporter 331
 U^x 140
 U^Z 140
 V 214–15, 227
 VA polyagglutination 520
 Vel 500–2
 frequency 500, 501
 Gerbich system association 417, 502
 inheritance 500–1
 VEL1 *see* Vel
 VEL2 *see* ABTI
 venous thromboembolism 68
 verotoxins 173
 Vg^a 339, 343, 343–4
Vibrio cholerae 66, 142, 517
Vicia graminea 138–9
Vicia unijuga 139

- viral infections 66–7
 DAF ligand 434
 glycophorins 142
 P antigen receptors 173–4
 VLAN *see* KEL25
 von Willebrand factor (vWF)
 67–8
 VONG *see* KEL28
 Vr **115**, 132
 VS 214–15, 227
 Vw **115**, 118, 126–7
- WARR 339, **343**, 343–4
 Wb **411**, 417
 Wd^a 339, **343**, 343–4
 weak D 195–6, 198, 202–3
 trans effect of *RHCE*C* 205
 weak Di^b 338
 weak E 209–10
 weak K 283–4
 WES^a 431–2
 WES^b 431–2
 WH 404, **405**
 Wiener's theory 185
 Wiskott–Aldrich syndrome, autoanti-i
 475
 Wk^a 287–8
 Wr^a 336, **337**, 340–1
 enzyme effects 341
 frequency **341**
 reducing agent effects 341
 Sd(a+++)⁺ gene linkage 506
 Wr(a–b–) 336, 342
 Wr^a/Wr^b dimorphism 341
 Wr^b 336, **337**, 340–1
 band 3 in expression 341–2
 depression in South-East Asian
 ovalocytosis 347
 enzyme effects 341
 reducing agent effects 341
- Wright antigens *see* Wr^a; Wr^b
 Wu 339, **343**, 343–4
- X chromosome
 inactivation 362–3
 CD99 gene 363
 XG gene 363
 XX gene 296
 pseudoautosomal region 363
 sex chromosome aneuploidy 366–7
 X-linkage 359
 XX males 359, 366
 X–Y interchange 366
XG gene 359, 363–5
 frequency 359, **360**
 inheritance 365
 location 360
 non-human primates 367–8
 organisation **364**, 364
Xg system 359–68
 CD99 polymorphism association
 365–6
 function 367
 polymorphism 365
 pseudoautosomal region 363
 sex chromosome aneuploidy 366–7
 X-chromosome inactivation 362–3
 XX males 359, 366
 see also *CD99*
XG1 *see* *Xg^a*
XG2 *see* *CD99*
Xg^a 359, 360–1, 366
 biochemistry 360–1
 development 361
 dosage 361
 enzyme effects 360
 in fibroblasts 361
 frequency 359
 inheritance 359–60, **361**
 loss 361
- non-human primates 367–8
 site density 361
XGR gene 360
 pseudoautosomal boundary location
 364, 366
 regulator locus 366
XIST gene 363
XX gene 278, 294
 erythropoiesis 295
 mutations 295
 X-chromosome inactivation 296
Xk protein 278, 280, 293–4
 Kell glycoprotein association 294–5
 X-linkage 359
XS2 259, 270
 XX males 359, 366
 X–Y interchange 366
- YG* gene 362
 Yk^a **440**, 441, 443–4
 Yt system 354–6, **355**
 Yt^a 354, 355–6
 development/distribution 356
 enzyme effects 355–6
 frequency 355
 inheritance 355
 molecular basis 355
 reducing agent effects 355–6
 Yt(a–b–) phenotype 354
 transient 356
 Yt^a/Yt^b polymorphism 355
 Yt^b 354, 355–6
 development/distribution 356
 enzyme effects 355–6
 frequency 355
 inheritance 355
 reducing agent effects 355–6
 Yus phenotype 410, 414–15
 ZENA 432